๐ European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis.
Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.(1,2) Severely affected patients are often treated with immune-modulating systemic drugs.(3,4) On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
keywords
๐ COVID-19 (1240)
๐ SARS-CoV-2 (551)
๐ atopic dermatitis (1)
๐ immunosuppressant (4)
๐ systemic therapy ()
๐ severe acute (1373)
๐ novel coronavirus (684)
๐ respiratory syndrome (2004)
๐ acute respiratory (1734)
author
๐ค Wollenberg, Andreas
๐ค Flohr, Carsten
๐ค Simon, Dagmar
๐ค Cork, Michael J
๐ค Thyssen, Jacob P
๐ค Bieber, Thomas
๐ค de Bruin-Weller, Marjolein S
๐ค Weidinger, Stephan
๐ค Deleuran, Mette
๐ค Taieb, Alain
๐ค Paul, Carle
๐ค Trzeciak, Magdalena
๐ค Werfel, Thomas
๐ค Seneschal, Julien
๐ค Barbarot, Sebastien
๐ค Darsow, Ulf
๐ค Torrelo, Antonio
๐ค Stalder, Jean-Francois
๐ค Svensson, Ake
๐ค Hijnen, Dirkjan
๐ค Gelmetti, Carlo
๐ค Szalai, Zsuzsanna
๐ค Gieler, Uwe
๐ค De Raeve, Linda
๐ค Kunz, Barbara
๐ค Spuls, Phyllis
๐ค von Kobyletzki, Laura B
๐ค Folster-Holst, Regina
๐ค Chernyshov, Pavel V
๐ค Cristen-Zaech, Stephanie
๐ค Heratizadeh, Annice
๐ค Ring, Johannes
๐ค Vestergaard, Christian
year
โฐ 2020
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]